MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-13-2026
Microbot Medical General and Administrative Expenses 2011-2026 | MBOT
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Microbot Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.46 M | 5 M | 4.13 M | 5.54 M | 5.2 M | 5.56 M | 4.03 M | 4.5 M | 4.01 M | 8.73 M | - | - | - | - | - | 9.38 M | 9.53 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.53 M | 4.01 M | 6.17 M |
Quarterly General and Administrative Expenses Microbot Medical
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.03 M | 2.69 M | 1.61 M | 1.56 M | - | 1.24 M | 1.09 M | 1.22 M | - | 932 K | 959 K | 1.3 M | - | 1.52 M | 1.37 M | 1.47 M | - | 1.16 M | 1.09 M | 1.27 M | - | 1.38 M | 1.22 M | 1.47 M | - | 948 K | 804 K | 1.33 M | - | 1.13 M | 1.14 M | 1.02 M | - | 896 K | 885 K | 7.3 K | - | -305 K | -74 K | -66 K | - | 14.1 K | 2.06 M | 2.69 M | - | 2.07 M | 2.14 M | 2.24 M | - | 1.71 M | 1.58 M | 1.89 M | - | 1.64 M | 1.78 M | 1.92 M | - | 1.73 M | 2.1 M | 2.08 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.03 M | -305 K | 1.37 M |
General and Administrative Expenses of other stocks in the Medical instruments industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
The Cooper Companies
COO
|
1.63 B | $ 60.08 | -0.5 % | $ 12 B |  USA |
 |
Atrion Corporation
ATRI
|
23.2 K | - | - | $ 810 M | USA |
 |
Luminex Corporation
LMNX
|
140 M | - | - | $ 1.75 B | USA |
 |
iRhythm Technologies
IRTC
|
493 M | $ 115.64 | 1.3 % | $ 3.7 B | USA |
 |
ICU Medical
ICUI
|
625 M | $ 120.74 | -1.83 % | $ 2.98 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
3.73 M | - | -9.52 % | $ 20.6 M | USA |
 |
Intuitive Surgical
ISRG
|
2.38 B | $ 425.83 | -0.52 % | $ 152 B | USA |
 |
Repro Med Systems
KRMD
|
23.4 M | $ 3.91 | -1.76 % | $ 181 M | USA |
 |
LeMaitre Vascular
LMAT
|
42 M | $ 97.36 | -2.15 % | $ 2.2 B | USA |
 |
Alcon
ALC
|
251 M | $ 63.82 | -0.31 % | $ 40.4 B |  Schweiz |
 |
Masimo Corporation
MASI
|
744 M | $ 178.36 | - | $ 9.51 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
62.8 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
198 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
8.44 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
941 M | - | -0.05 % | $ 10.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
9.99 M | - | - | $ 28.6 M | USA |
 |
Envista Holdings Corporation
NVST
|
1.16 B | $ 23.62 | -0.96 % | $ 3.97 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
671 M | - | -0.02 % | $ 16.3 B | USA |
 |
electroCore
ECOR
|
38.2 M | $ 6.08 | -5.52 % | $ 51.6 K | USA |
 |
Haemonetics Corporation
HAE
|
437 M | $ 57.3 | 0.37 % | $ 2.88 B | USA |
 |
STAAR Surgical Company
STAA
|
85.8 M | $ 32.72 | 2.22 % | $ 1.62 B | USA |
 |
STERIS plc
STE
|
1.33 B | $ 213.38 | -1.2 % | $ 21 B | USA |
 |
Teleflex Incorporated
TFX
|
720 M | $ 129.54 | -0.57 % | $ 5.78 B | USA |
 |
Isoray
ISR
|
30.2 M | - | 0.03 % | $ 108 M | USA |
 |
Glaukos Corporation
GKOS
|
224 M | $ 142.4 | 0.16 % | $ 6.9 B | USA |
 |
InfuSystem Holdings
INFU
|
57 M | $ 8.73 | 1.39 % | $ 180 M | USA |
 |
Milestone Scientific
MLSS
|
11.6 M | $ 0.33 | -2.12 % | $ 27.1 M | USA |
 |
Merit Medical Systems
MMSI
|
455 M | $ 61.83 | -1.17 % | $ 3.66 B | USA |
 |
Utah Medical Products
UTMD
|
7.88 M | $ 63.27 | -0.68 % | $ 205 M | USA |
 |
West Pharmaceutical Services
WST
|
394 M | $ 303.19 | 1.0 % | $ 21.9 B | USA |
 |
Pulse Biosciences
PLSE
|
32 M | $ 24.21 | -10.66 % | $ 1.63 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.44 B | $ 9.98 | -4.13 % | $ 1.99 B | USA |
 |
Retractable Technologies
RVP
|
12.8 M | $ 0.69 | - | $ 20.7 M | USA |
 |
Pro-Dex
PDEX
|
4.84 M | $ 59.84 | 2.03 % | $ 197 M | USA |
 |
Predictive Oncology
POAI
|
25.9 M | - | - | $ 31.1 M | USA |
 |
BioLife Solutions
BLFS
|
45.5 M | $ 20.52 | -2.56 % | $ 980 M | USA |
 |
Stereotaxis
STXS
|
17.8 M | $ 1.88 | -3.34 % | $ 171 M | USA |
 |
Baxter International
BAX
|
2.89 B | $ 17.32 | -2.62 % | $ 8.89 B | USA |
 |
ResMed
RMD
|
739 M | $ 203.11 | 0.32 % | $ 29.7 B | USA |
 |
AtriCure
ATRC
|
311 M | $ 28.04 | -0.41 % | $ 1.34 B | USA |
 |
Harvard Bioscience
HBIO
|
17.7 M | $ 5.34 | -3.26 % | $ 237 M | USA |
 |
NeuroMetrix
NURO
|
6.33 M | - | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
42.1 M | $ 10.92 | -1.0 % | $ 446 M | USA |
 |
Becton, Dickinson and Company
BDX
|
5.28 B | $ 142.12 | -1.63 % | $ 40.9 B | USA |
 |
Nephros
NEPH
|
9 M | $ 3.27 | -2.1 % | $ 34.7 M | USA |
 |
OraSure Technologies
OSUR
|
47.7 M | $ 3.12 | 5.59 % | $ 229 M | USA |
 |
Repligen Corporation
RGEN
|
291 M | $ 106.1 | 2.63 % | $ 5.97 M | USA |